Sendero Wealth Management LLC Boosts Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Sendero Wealth Management LLC grew its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 25.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 45,221 shares of the medical research company's stock after purchasing an additional 9,153 shares during the period. IQVIA makes up about 1.3% of Sendero Wealth Management LLC's holdings, making the stock its 15th largest holding. Sendero Wealth Management LLC's holdings in IQVIA were worth $8,886,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in IQV. Nordea Investment Management AB raised its stake in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock worth $277,908,000 after purchasing an additional 452,029 shares during the period. Simplify Asset Management Inc. raised its position in shares of IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company's stock valued at $2,284,000 after buying an additional 3,894 shares during the period. Versor Investments LP acquired a new position in IQVIA in the third quarter valued at approximately $1,328,000. JPMorgan Chase & Co. grew its position in IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after acquiring an additional 583,396 shares during the period. Finally, CIBC Asset Management Inc increased its stake in IQVIA by 3.3% during the third quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company's stock worth $62,501,000 after acquiring an additional 8,490 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of research analyst reports. The Goldman Sachs Group lowered their price target on IQVIA from $280.00 to $250.00 and set a "buy" rating for the company in a report on Friday, November 1st. Stephens began coverage on shares of IQVIA in a research note on Friday, December 20th. They set an "overweight" rating and a $250.00 target price for the company. Morgan Stanley reduced their price target on shares of IQVIA from $280.00 to $265.00 and set an "overweight" rating on the stock in a research note on Monday, November 4th. William Blair reaffirmed an "outperform" rating on shares of IQVIA in a research report on Wednesday, December 11th. Finally, BTIG Research cut their target price on IQVIA from $290.00 to $260.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $255.82.

IQVIA Stock Up 0.8 %

Shares of IQV stock traded up $1.61 on Thursday, reaching $197.71. 1,208,107 shares of the stock were exchanged, compared to its average volume of 1,297,661. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a market capitalization of $35.89 billion, a price-to-earnings ratio of 25.95, a PEG ratio of 2.09 and a beta of 1.48. The business's 50 day moving average price is $200.93 and its 200 day moving average price is $221.44.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.